Amneal Pharmaceuticals (AMRX) announced that the FDA has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which ...

As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in ...

Participants received 5 mg donepezil daily or matching placebo for 2 weeks, then donepezil at 10 mg daily or matching placebo for 8 weeks; treatment was discontinued at 10 weeks, with an ...

has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which references Abbvie’s NAMZARIC®, and Everolimus 2 mg, 3 mg and 5 mg extended-release capsules, which ...

The researchers, clinical operators, and efficacy evaluator are independent. The donepezil tablets (specification: 5 mg × 14 tablets, ZEN Biotechnology Co., Ltd., Chongqing, China) are taken before ...

The company announced today that it has launched memantine/donepezil extended-release capsules ... tentative approval to Amneal's rifaximin 550 mg oral tablets for adults with irritable bowel ...

BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), a pharmaceutical company with a market capitalization of ...

The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...

In our study, there were no differences in cognitive performance between the groups given donepezil or placebo ... reported improved mean MMSE score (+1.5 points) after one year and a minimal ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...